Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech has announced the appointment of Thomas Schmidt as the Interim Chief Financial Officer, effective November 1, 2024, succeeding Jesper Nissen. Schmidt brings over 30 years of financial management experience, primarily in the life science industry, and has previously held significant roles at Roche and Ambu. His contract entails a monthly salary of roughly 32,450 USD and provisions for termination with one month’s notice after the initial two months.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
